Pharsight

Namzaric generic

Namzaric is an Alzheimer’s disease medication owned by Allergan. It contains Donepezil Hydrochloride and Memantine Hydrochloride as active ingredients. Namzaric was first authorized for market use on 23 December 2014.

When will Namzaric generic be available?

The last patent for Namzaric will expire on 5th December 2029, after which its generic version can be legally produced and sold. This patent holds the keys to the modified release formulations of memantine oral dosage forms. The generics of Namzaric will be possible due to this patent expiry.

Namzaric uses

Namzaric is used as a combination of Memantine HCL/Donepezil HCL for the treatment of moderate to severe dementia of the Alzheimer's type. It comes in an extended-release oral capsule form. Its active ingredients, Donepezil Hydrochloride and Memantine Hydrochloride, work together to reduce symptoms and slow the progression of memory loss associated with Alzheimer's.

Namzaric patent expiration

Namzaric holds 19 patents, none of which have expired. The patents cover different key aspects of the drug and its formulation. A considerable number of these patents are going to expire in 2025, but the last patent will not expire until 5th December 2029, which pertains to its modified release formulations. The expiration of this patent will pave the way for the creation of Namzaric generics. Below are the details of the patents:

EPO Oppostions filed on Namzaric

Litigations filed on Namzaric

Namzaric dosage

Want to ask something?